Jordi F. Anton

Barcelona, CT, ES

Expertise in

conditions

Barcelona, CT, ES

Overview

Jordi Anton practices practicing medicine in Barcelona, Spain.

Anton is highly rated in 34 conditions, according to our data. Their clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Mevalonate Kinase Deficiency, Scleroderma, Kawasaki Disease, and Bone Marrow Aspiration.

They are actively involved in clinical research, co-authoring 159 peer reviewed articles and participating in 4 clinical trials.

Locations

Barcelona, CT, Spain

Other Locations

Esplugues De Llobregat, CT, Spain

Sant Joan Despi, CT, Spain

Vilafranca Del Penedes, CT, Spain

Sant Joan, PM, Spain

Valencia, VC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Enrollment Status: Active_not_recruiting

Publish Date: March 19, 2026

Intervention Type: Drug

Study Drugs: Ixekizumab, Adalimumab

Study Phase: Phase 3

Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes

Enrollment Status: Unknown

Publish Date: November 30, 2023

A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody

Enrollment Status: Completed

Publish Date: June 28, 2022

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

A Pilot, Open-label, Single Arm, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Enrollment Status: Completed

Publish Date: May 17, 2022

Intervention Type: Drug

Study Drug: Emapalumab Anti-IFN-Gamma Antibody

Study Phase: Phase 2

View 3 Less Clinical Trials

159 Total Publications

What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?

Journal: Expert review of clinical immunology

Published: May 05, 2026

View All 159 Publications

Frequently Asked Questions about Jordi F. Anton

Is Jordi F. Anton a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Jordi F. Anton is classified as an Elite expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jordi F. Anton participate in research or clinical trials?

Yes. Jordi F. Anton has published 159 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Jordi F. Anton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Anton's expertise for a condition

ConditionClose